Nurix Therapeutics (Nasdaq (NRIX) is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Nurix’s wholly owned pipeline comprises targeted protein degraders of Bruton’s tyrosine kinase (Btk), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B (Cbl-B), an E3 ligase that regulates T cell activation.
Bain Capital Healthcare
We have built one of the largest and deepest healthcare investing teams in the world. Click here to read more about the breadth and legacy of our efforts.